Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin
- 1 March 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (4) , 563-570
- https://doi.org/10.1016/j.ejca.2003.11.023
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancerAnnals of Oncology, 2001
- Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than PaclitaxelJournal of Clinical Oncology, 2001
- Preclinical antitumor activity of two novel taxanesCancer Chemotherapy and Pharmacology, 2001
- Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor ELCancer Chemotherapy and Pharmacology, 1999
- The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardiumThe FASEB Journal, 1998
- Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.Journal of Clinical Oncology, 1997
- Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.Journal of Clinical Oncology, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Reporting results of cancer treatmentCancer, 1981